Everardo Hegewisch Solloa
ImmuneBridge, Inc, CA, United States
Presentations this author is a contributor to:
Donor Selection for Allogeneic Immunotherapy Using High-Throughput Screening of HSC-derived Natural Killer Cells (#141)
4:45 PM
Nina Horowitz
Poster Session One
Functional characterization of expanded HSC-derived NK cells, an optimal source for allogeneic cell therapy (#142)
4:45 PM
Nina Horowitz
Poster Session One